The Readout Loud

This all-AI podcast episode discusses how researchers and pharmaceutical firms are using AI in medicine for finding new drug targets, designing therapies, and improving clinical trials. It explores AI in biotech, including startup financing, AI hype, and potential applications in manufacturing and regulatory filings. The podcast also delves into the challenges of using AI in drug discovery and the limitations of chat for IND filings. The speakers touch on the need for neuro symbolic AI and traceability in medicine.

In this episode, the hosts discuss the debate over Vertex Pharmaceuticals' novel pain drug and its clinical trial results. They also touch upon the farewell to the drug Aduhelm, Biogen's decision to give back the rights to the treatment, and the retirement of an FDA icon. The chapter explores the controversies surrounding the drug VX 548 in pain management, including addiction concerns and market reactions. The episode concludes with discussions on an influential FDA figure's experiences and the changing dynamics in the industry.

Biotech's downturn affects startups and venture capitalists. Gilead struggles to become an oncology company. A major pharma firm acquires a biotech company. Challenges faced by VCs in funding biotech. Gilead focuses on CAR-T therapy and its acquisition strategies.

Biotech startups are laying off employees and adjusting strategies due to a tough market. Major biotech stories in 2024 include data readouts and FDA decisions. The impact of the JP Morgan conference on biotech stocks is discussed along with the future of the industry. Specific topics covered include a drug for fatty liver disease, Eli Lilly's Alzheimer's treatment, biomulicar condensates, and the challenges of funding and generating value in biotech.

Discussion of recent acquisitions and outlook for M&A activity in biotech. Intersection between biotech and Nvidia, including investments and regulatory flexibility. Experiences and networking at the JP Morgan conference parties. Insights from industry parties and future ventures.

It's our last episode of 2023, so we look back on the biggest stories of the year, discuss the best and worst CEOs in the industry, and make some reasonably informed guesses on what 2024 has in store for the drug industry.

FTC blocks Sanofi-Maze Therapeutics deal, Pfizer's downbeat future, Vertex's next big thing, and Reed Jobs' journey into biotech venture capital.

Megan Molteni discusses the history and future of CRISPR-based medicine and the expected FDA approval of the first CRISPR-based medicine. Bruce Booth joins to discuss the challenges faced by the biotech industry and prospects for optimism in 2024.

AbbVie, a company spending $10 billion on a cancer-focused company on its first FDA approval. Implications for biotech in 2023 and oncology. Safety concerns for CAR-T cancer treatment. Slumping industry job market. Curious explanations for clinical failures.

Investigative reporter Casey Ross reveals how UnitedHealth Group used an algorithm to deny patient care for profit. Biotech veteran Michael Gilman talks about being a startup CEO in the economic downturn and shares cocktail recipes. They also discuss the approval of a groundbreaking CRISPR-based medicine.